Research on the effects of interleukin-6 on proliferation of cervical cancer cell C-33A_West China Medical Journal

Authors：

TANG Lin , WANG Qilin ,  WANG Ping

Emergency Department of Obsterics and Gynecology, West China Second Hospital, Sichuan University/Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education; Chengdu, Sichuan 610041, P. R. China;

Corresponding author：

WANG Ping, Email: wangping_886@126.com

Keywords：

Cervical cancer; Interleukin-6; Epithelial-mesenchymal transition

DOI：

10.7507/1002-0179.201803148

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

ObjectiveTo explore the role of interleukin-6 (IL-6) in cervical cancer cell C-33A.MethodsThe cervical cancer cells C-33A were divided into the IL-6 group and the control group after culture. The IL-6 group were treated with 50 ng/mL of recombinant IL-6 protein, and the control group were without IL-6. Then cell viability and cell migration were detected by MTT assay and wound-healing assay, respectively. The mRNA and protein expressions of epithelial-cadherin (E-Cad), neural-cadherin (N-Cad), vimentin and transcription factors-snail1 (TFs-SNAIL1) were analyzed by real time quantitative polymerase chain reaction and Western blotting, respectively.ResultsCompared with the control group, in the IL-6 group the proliferation of cervical cancer cells C-33A was promoted (12 h: 0.388±0.025 vs. 0.597±0.057; 24 h: 0.547±0.021 vs. 0.798±0.036; 48 h: 0.745±0.056 vs. 1.296±0.122; 72 h: 1.074±0.053 vs. 1.805±0.113; P<0.05), and the relative migration ability of cervical cancer cell was promoted (12 h: 1.057±0.029vs. 1.200±0.045; 24 h: 1.189±0.036 vs. 1.428±0.181; 48 h: 1.273±0.059 vs. 1.569±0.143; 72 h: 1.409±0.047 vs. 1.623±0.170; P<0.05); meanwhile, compared with the control group, in the IL-6 group, the expression of E-Cad mRNA (1.012±0.098vs. 0.483±0.171, P<0.01) and E-Cad protein (1.032±0.015vs. 0.395±0.119; P<0.01) decreased, the expression of N-Cad mRNA (1.054±0.106vs. 1.465±0.230, P<0.01) and N-Cad protein (1.040±0.043vs. 1.605±0.128, P<0.01) increased, the expression of vimentin mRNA (1.050±0.083vs. 1.340±0.099, P<0.05) and vimentin protein (1.043±0.062vs. 1.430±0.077, P<0.05) increased, and the expression of TFs-SNAIL1 mRNA (1.058±0.176vs. 1.510±0.229, P<0.01) and Fs-SNAIL1 protein (1.022±0.015vs. 1.470±0.139, P<0.01) increased.ConclusionIL-6 may promote the proliferation, migration, and epithelial-mesenchymal transition of cervical cancer cell C-33A.

Citation： TANG Lin, WANG Qilin, WANG Ping. Research on the effects of interleukin-6 on proliferation of cervical cancer cell C-33A. West China Medical Journal, 2018, 33(4): 423-426. doi: 10.7507/1002-0179.201803148 Copy

1.	Forouzanfar MH, Foreman KJ, Delossantos AM, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet, 2011, 378(9801): 1461-1484.
2.	Bouvard V, Baan R, Straif K, et al. A review of human carcinogens--Part B: biological agents. Lancet Oncol, 2009, 10(4): 321-322.
3.	Insinga RP, Perez G, Wheeler CM, et al. Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance. Cancer Epidemiol Biomarkers Prev, 2011, 20(2): 287-296.
4.	Torres-Poveda K, Burguete-Garcia AI, Cruz MA, et al. The SNP at-592 of human IL-10 gene is associated with serum IL-10 levels and increased risk for human papillomavirus cervical lesion development. Infect Agent Cancer, 2012, 7(1): 32-40.
5.	Torres-Poveda K, Burguete-García AI, Bahena-Román M, et al. Risk allelic load in Th2 and Th3 cytokines genes as biomarker of susceptibility to HPV-16 positive cervical cancer: a case control study. BMC Cancer, 2016, 16: 330.
6.	Zhang X, Zhang L, Tian C, et al. Genetic variants and risk of cervical cancer: epidemiological evidence, meta-analysis and research review. BJOG, 2014, 121(6): 664-673.
7.	Castrilli G, Tatone D, Diodoro MG, et al. Interluekin 1-alpha and interluekin-6 promote the in vitro growth of both normol and neoplastic human cervical epithelial cells. Br J Cancer, 1997, 75(6): 855-859.
8.	Iglesias M, Plowman GD, Woodworth CD. Interleukin-6 and interleukin-6 solube receptor regulate proliferation of normal, human papillomavirus-immortalized, and carcinoma-derived cervical cells in vitro. Am J Pathol, 1995, 146(4): 944-952.
9.	Wei LH, Kuo ML, Chen C, et al. The anti-role of interleukin-6 in human cervical cancer is mediated by up regulation of Mcl-1 through a PI3-K/Akt pathway. Oncogene, 2001, 20(41): 5799-5809.
10.	Kumari N, Dwarakanath BS, Das A, et al. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol, 2016, 37(9): 11553-11572.
11.	孙杰, 付立芳. IL-6 通过调控 miR-152/PIK3R3 通路促进胃癌细胞的增殖和上皮-间质转化. 中南大学学报: 医学版, 2017, 42(11): 1241-1247.
12.	童丹, 宋文静. IL-17、IL-6 和 TGF-β_1 在宫颈上皮内瘤变和宫颈癌中的表达及临床意义. 中国妇幼保健, 2014, 29(24): 3984-3986.
13.	Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell, 2010, 140(6): 883-899.
14.	Azarpira N, Dehghani M, Darai M. The interleukin-6 andvascular endothelial growth factor in hematopoietic stem cell transplantation. Saudi J Kidney Dis Transpl, 2012, 23(3): 521-525.
15.	Bharti R, Dey G, Mandal M. Cancer development, chemoresistance, epithelial to mesenchymal transition and stem cells: a snapshot of IL-6 mediated involvement. Cancer Lett, 2016, 375(1): 51-61.
16.	孙兰颖, 李治田, 武志钦, 等. VEGFIL-6 在宫颈癌中的表达及其二者的相互关系. 中国肿瘤临床, 2005, 32(22): 1287-1289.

1. Forouzanfar MH, Foreman KJ, Delossantos AM, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet, 2011, 378(9801): 1461-1484.
2. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens--Part B: biological agents. Lancet Oncol, 2009, 10(4): 321-322.
3. Insinga RP, Perez G, Wheeler CM, et al. Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance. Cancer Epidemiol Biomarkers Prev, 2011, 20(2): 287-296.
4. Torres-Poveda K, Burguete-Garcia AI, Cruz MA, et al. The SNP at-592 of human IL-10 gene is associated with serum IL-10 levels and increased risk for human papillomavirus cervical lesion development. Infect Agent Cancer, 2012, 7(1): 32-40.
5. Torres-Poveda K, Burguete-García AI, Bahena-Román M, et al. Risk allelic load in Th2 and Th3 cytokines genes as biomarker of susceptibility to HPV-16 positive cervical cancer: a case control study. BMC Cancer, 2016, 16: 330.
6. Zhang X, Zhang L, Tian C, et al. Genetic variants and risk of cervical cancer: epidemiological evidence, meta-analysis and research review. BJOG, 2014, 121(6): 664-673.
7. Castrilli G, Tatone D, Diodoro MG, et al. Interluekin 1-alpha and interluekin-6 promote the in vitro growth of both normol and neoplastic human cervical epithelial cells. Br J Cancer, 1997, 75(6): 855-859.
8. Iglesias M, Plowman GD, Woodworth CD. Interleukin-6 and interleukin-6 solube receptor regulate proliferation of normal, human papillomavirus-immortalized, and carcinoma-derived cervical cells in vitro. Am J Pathol, 1995, 146(4): 944-952.
9. Wei LH, Kuo ML, Chen C, et al. The anti-role of interleukin-6 in human cervical cancer is mediated by up regulation of Mcl-1 through a PI3-K/Akt pathway. Oncogene, 2001, 20(41): 5799-5809.
10. Kumari N, Dwarakanath BS, Das A, et al. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol, 2016, 37(9): 11553-11572.
11. 孙杰, 付立芳. IL-6 通过调控 miR-152/PIK3R3 通路促进胃癌细胞的增殖和上皮-间质转化. 中南大学学报: 医学版, 2017, 42(11): 1241-1247.
12. 童丹, 宋文静. IL-17、IL-6 和 TGF-β_1 在宫颈上皮内瘤变和宫颈癌中的表达及临床意义. 中国妇幼保健, 2014, 29(24): 3984-3986.
13. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell, 2010, 140(6): 883-899.
14. Azarpira N, Dehghani M, Darai M. The interleukin-6 andvascular endothelial growth factor in hematopoietic stem cell transplantation. Saudi J Kidney Dis Transpl, 2012, 23(3): 521-525.
15. Bharti R, Dey G, Mandal M. Cancer development, chemoresistance, epithelial to mesenchymal transition and stem cells: a snapshot of IL-6 mediated involvement. Cancer Lett, 2016, 375(1): 51-61.
16. 孙兰颖, 李治田, 武志钦, 等. VEGFIL-6 在宫颈癌中的表达及其二者的相互关系. 中国肿瘤临床, 2005, 32(22): 1287-1289.

West China Medical Journal

Research on the effects of interleukin-6 on proliferation of cervical cancer cell C-33A

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content